Ilumetri

RSS

tildrakizumab

Authorised
This medicine is authorised for use in the European Union.

Overview

Ilumetri is a medicine that acts on the immune system and is used to treat plaque psoriasis, a disease causing red, scaly patches on the skin. It is used in adults with moderate to severe disease for whom treatments applied to the skin are not suitable.

Ilumetri contains the active substance tildrakizumab.

This EPAR was last updated on 16/04/2019

Authorisation details

Product details
Name
Ilumetri
Agency product number
EMEA/H/C/004514
Active substance
tildrakizumab
International non-proprietary name (INN) or common name
tildrakizumab
Therapeutic area (MeSH)
Psoriasis
Anatomical therapeutic chemical (ATC) code
L04AC
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Almirall S.A
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
17/09/2018
Contact address
Ronda General Mitre
151 08022 Barcelona
Spain

Product information

21/03/2019 Ilumetri - EMEA/H/C/004514 - N/0004

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Immunosuppressants

  • Interleukin inhibitors

Therapeutic indication

Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
1 rating
2 ratings